189 related articles for article (PubMed ID: 7559734)
1. Bone metabolic markers in bone metastases.
Koizumi M; Yamada Y; Takiguchi T; Nomura E; Furukawa M; Kitahara T; Yamashita T; Maeda H; Takahashi S; Aiba K
J Cancer Res Clin Oncol; 1995; 121(9-10):542-8. PubMed ID: 7559734
[TBL] [Abstract][Full Text] [Related]
2. Correlation between bone metabolic markers and bone scan in prostatic cancer.
Maeda H; Koizumi M; Yoshimura K; Yamauchi T; Kawai T; Ogata E
J Urol; 1997 Feb; 157(2):539-43. PubMed ID: 8996351
[TBL] [Abstract][Full Text] [Related]
3. [Serum concentration of pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen (ICTP) and carboxyterminal propeptide of human type I procollagen (PICP) in the diagnosis of bone metastases].
Koizumi M; Yamada Y; Takiguchi T; Suzuki C; Akashi T; Nomura E; Yamashita T; Ogata E
Kaku Igaku; 1996 Jan; 33(1):77-84. PubMed ID: 8819718
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of tumor metastasis to the bone: challenges and opportunities.
Reddi AH; Roodman D; Freeman C; Mohla S
J Bone Miner Res; 2003 Feb; 18(2):190-4. PubMed ID: 12568395
[TBL] [Abstract][Full Text] [Related]
6. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
7. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of carboxyterminal propeptide of type I procollagen in cancer patients with osteoblastic and osteolytic bone metastases.
Piovesan A; Berruti A; Osella G; Raucci CA; Torta M; Dogliotti L; Angeli A
Int J Biol Markers; 1994; 9(4):243-6. PubMed ID: 7836803
[TBL] [Abstract][Full Text] [Related]
9. Markers of bone metabolism in prostate cancer.
Smith MR
Cancer Treat Rev; 2006; 32 Suppl 1():23-6. PubMed ID: 16680835
[TBL] [Abstract][Full Text] [Related]
10. Expressiveness of Bone Markers in Breast Cancer with Bone Metastases.
Zulauf N; Brüggmann D; Groneberg D; Oremek GM
Oncology; 2019; 97(4):236-244. PubMed ID: 31412345
[TBL] [Abstract][Full Text] [Related]
11. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
[TBL] [Abstract][Full Text] [Related]
13. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients.
Leeming DJ; Koizumi M; Byrjalsen I; Li B; Qvist P; Tankó LB
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):32-8. PubMed ID: 16434583
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. [Bone metastasis from prostate cancer].
Uemura M; Nonomura N
Clin Calcium; 2014 Aug; 24(8):1169-75. PubMed ID: 25065868
[TBL] [Abstract][Full Text] [Related]
16. Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer.
Houzé P; Bellik B; Extra JM; Bouro F; Bousquet B
Clin Chim Acta; 1999 Mar; 281(1-2):77-88. PubMed ID: 10217629
[TBL] [Abstract][Full Text] [Related]
17. Biochemical parameters of bone metabolism in bone metastases of solid tumors (review).
Meijer WG; van der Veer E; Willemse PH
Oncol Rep; 1998; 5(1):5-21. PubMed ID: 9458286
[TBL] [Abstract][Full Text] [Related]
18. [CT findings of bone metastasis].
Nosaki T; Murai T; Okumura A; Furuki T; Mori K; Tsuji S; Nakanishi K; Kobayashi M; Fukui A; Fujii K
Rinsho Hoshasen; 1989 Sep; 34(9):991-7. PubMed ID: 2810844
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer.
Noguchi M; Yahara J; Noda S
Urology; 2003 May; 61(5):993-8. PubMed ID: 12736022
[TBL] [Abstract][Full Text] [Related]
20. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]